



ANDA 76-344

Food and Drug Administration  
Rockville MD 20857

FEB 11 2004

Ranbaxy Pharmaceuticals, Inc.  
Attention: Abha Pant  
U.S. Agent for: Ranbaxy Laboratories Limited  
600 College Road East  
Princeton, NJ 08540

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 31, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Benazepril Hydrochloride Tablets, 5 mg, 10 mg, 20 mg, and 40 mg.

Reference is made to the tentative approval letters issued by this office on February 26, and August 25, 2003, and to your amendments dated August 6, and August 12, 2002; November 11, December 4, and December 23, 2003; and February 3, 2004.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Benazepril Hydrochloride Tablets, 5 mg, 10 mg, 20 mg, and 40 mg to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Lotensin<sup>®</sup> Tablets 5 mg, 10 mg, 20 mg, and 40 mg of Novartis Pharmaceuticals Corp.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FDA 2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

(b)(6)

Gary Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research